Bayer (FRA:BAYN) received a €125.00 ($154.32) price target from analysts at UBS Group in a note issued to investors on Monday, www.boersen-zeitung.de reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS Group’s target price indicates a potential upside of 24.38% from the stock’s current price.
Other analysts have also issued reports about the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Bayer in a report on Friday, October 20th. Sanford C. Bernstein set a €129.00 ($159.26) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Wednesday, January 17th. Deutsche Bank set a €124.00 ($153.09) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Monday, October 16th. Independent Research set a €120.00 ($148.15) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Friday, October 13th. Finally, Baader Bank set a €140.00 ($172.84) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company’s stock. Bayer presently has an average rating of “Buy” and an average target price of €121.71 ($150.26).
Shares of Bayer (FRA BAYN) opened at €100.50 ($124.07) on Monday. Bayer has a 1-year low of €99.76 ($123.16) and a 1-year high of €123.82 ($152.86). The company has a market cap of $82,780.00 and a PE ratio of 23.76.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.